2023-10-23 | NDAQ:MRUS | Press Release
(2023-10-23 | NDAQ:MRUS) Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
Source: stockhouse.com
Page 4 - Corp Comms News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Corp Comms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Corp Comms Today - Breaking & Trending Today
Merus Announces Business Update Conference Call - Merus (NASDAQ:MRUS)
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported
Source: benzinga.com
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acc
Source: yahoo.com
Planview Named a Leader in the 2023 Gartner® Magic Quadrant™ for Adaptive Project Management and Reporting
Planview positioned highest in execution and furthest in vision
Source: ibtimes.com.au
Merus Announces Pricing of Public Offering of Common Shares - Merus (NASDAQ:MRUS)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), a clinical-stage oncology company developing innovative, full-length
Source: benzinga.com